Alvotech Holdings S.A
Develops and manufactures affordable biosimilar medicines for global patient access.
ALVO | LU
Overview
Corporate Details
- ISIN(s):
- LU2458332611
- LEI:
- 222100DCZBOWV5DZ8372
- Country:
- Luxembourg
- Address:
- 9, RUE DE BITBOURG, L-1273 LUXEMBOURG
- Website:
- https://www.alvotech.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Alvotech is a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines. The company's mission is to improve lives by increasing patient access to high-quality, affordable biologic treatments worldwide. Alvotech operates a vertically integrated platform, managing the entire process from cell line development to fill-and-finish manufacturing. This end-to-end approach provides control, scale, and speed in its development and production processes. For global commercialization, the company forms strategic partnerships with third parties to market and distribute its robust pipeline of biosimilars to patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-22 12:15 |
Regulatory News Service
Evrópska lyfjastofnunin mælir með útgáfu markaðsleyfis fyrir AVT03, fyrirhugaða…
|
Icelandic | 6.1 KB | ||
| 2025-09-22 12:15 |
Regulatory News Service
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech…
|
English | 13.5 KB | ||
| 2025-09-22 10:30 |
Regulatory News Service
Lyfjastofnun Evrópu mælir með leyfi til markaðssetningar á Gobivaz, fyrirhugaðr…
|
Icelandic | 7.6 KB | ||
| 2025-09-22 10:30 |
Regulatory News Service
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's…
|
English | 17.0 KB | ||
| 2025-09-19 13:45 |
Regulatory News Service
Markaðsleyfi veitt í Japan fyrir þrjár nýjar líftæknilyfjahliðstæður frá Alvote…
|
Icelandic | 6.0 KB | ||
| 2025-09-19 13:45 |
Regulatory News Service
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
|
English | 12.1 KB | ||
| 2025-08-21 10:30 |
Regulatory News Service
Alvotech hlýtur leyfi til markaðssetningar í Evrópu á hliðstæðu við augnlyfið E…
|
Icelandic | 7.4 KB | ||
| 2025-08-21 10:30 |
Regulatory News Service
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar …
|
English | 17.6 KB | ||
| 2025-08-13 22:15 |
Earnings Release
Alvotech birtir uppgjör fyrir fyrstu sex mánuði ársins og kynnir nýjustu áfanga…
|
Icelandic | 41.2 KB | ||
| 2025-08-13 22:15 |
Earnings Release
Alvotech Reports Results for the First Six Months of 2025 and Provides a Busine…
|
English | 48.1 KB | ||
| 2025-08-06 14:00 |
Report Publication Announcement
Alvotech kynnir uppgjör fyrri helmings ársins 2025 þann 14. ágúst nk. kl. 12 á …
|
Icelandic | 3.8 KB | ||
| 2025-08-06 14:00 |
Report Publication Announcement
Alvotech Announces Webcast to Report Financial Results for the First Half of 20…
|
English | 6.0 KB | ||
| 2025-07-28 23:35 |
Report Publication Announcement
Skjöl lögð inn til Verðbréfaeftirlits Bandaríkjanna (SEC)
|
Icelandic | 775 bytes | ||
| 2025-07-28 23:35 |
Foreign Filer Report
Information filed with the U.S. Securities and Exchange Commission
|
English | 785 bytes | ||
| 2025-07-10 10:40 |
Board/Management Information
Alvotech skipar Lindu Jónsdóttur í stöðu framkvæmdastjóra fjármálasviðs
|
Icelandic | 6.9 KB |
Automate Your Workflow. Get a real-time feed of all Alvotech Holdings S.A filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Alvotech Holdings S.A via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
